Payment overview · 2025
General Payments
$578.89
32 reported records · 12 companies
Healthcare provider profile · identity verified
Mark E Henderson, DO
Allopathic & Osteopathic Physicians|Family Medicine · LINCOLN, NE · NPI 1760902498
Verified facts
What the public records show
CMS Open Payments records show Mark E Henderson, DO received $578.89 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Prolia, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.78 | 23.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.83 | 17.8% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.51 | 11.3% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.34 | 11.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.47 | 9.4% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $46.58 | 8.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.55 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.97 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.64 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.78 | 3.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.46 | 2.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.98 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $578.89 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.06 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.70 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.51 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $64.34 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $46.58 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 55 |
| Omeprazole | Omeprazole | 200 | 60 |
| Losartan Potassium | Losartan Potassium | 183 | 61 |
| Lisinopril | Lisinopril | 182 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 169 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 36 |
| Metformin Hcl | Metformin Hcl | 106 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 32 |
| Eliquis | Apixaban | 82 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 20 |
| Gabapentin | Gabapentin | 77 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 22 |
| Simvastatin | Simvastatin | 73 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 22 |
| Ozempic | Semaglutide | 68 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 35 |
| Trazodone Hcl | Trazodone Hcl | 62 | 20 |
| Meloxicam | Meloxicam | 60 | 19 |
| Metformin Hcl Er | Metformin Hcl | 60 | 15 |
| Buspirone Hcl | Buspirone Hcl | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 16 |
| Jardiance | Empagliflozin | 57 | 21 |
| Potassium Chloride | Potassium Chloride | 57 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 51 | 12 |
| Valsartan | Valsartan | 51 | 16 |
| Furosemide | Furosemide | 50 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 14 |
| Mounjaro | Tirzepatide | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 20 |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Spironolactone | Spironolactone | 41 | 17 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Sertraline Hcl | Sertraline Hcl | 35 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Famotidine | Famotidine | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Prednisone | Prednisone | 29 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 13 |
| Carvedilol | Carvedilol | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $578.89 · 32 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, EVENITY, FARXIGA, IBSRELA, Kerendia, Korlym, NEXPLANON, Ozempic, PROLIA, QULIPTA, Qelbree, VERQUVO, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error